Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 March 2022 | Story Lunga Luthuli | Photo Charl Devenish
UFS staff members
All smiles – pictured are inspired University of the Free State staff ready to live, serve with excellence, and care for the growth of the institution.

The Division of Organisational Development and Employee Well-being within the Department of Human Resources’ iRecognise initiative is another University of the Free State (UFS) initiative to appreciate and recognise staff dedication and excellence. 

Through the peer-to-peer iRecognise platform, UFS staff members have the opportunity to recognise colleagues from different units, divisions, faculties, and campuses. 

Natasha Nel, UFS Organisational Development specialist, said: “iRecognize is an open acknowledgment and expressed appreciation for employees’ contributions. A strong recognition culture can help individuals and organisations perform better. Employees, teams, and the university all benefit from frequent and meaningful feedback and appreciation.”

“It is a promotion of positive behaviour that supports individuals, teams, divisions, and departments in achieving the university’s vision and goals. The UFS wants to create a culture of mutual respect, reward, and recognition for employees at all levels in a non-monetary award based on significance,” she said.

The criteria for staff to recognise colleagues include timeliness, authenticity, and specificity, and the badges that staff members can use is also aligned with the university’s competency framework. The platform also includes an option to send recognition privately. 

“Employees who feel recognised and appreciated are more engaged, productive, and innovative, despite what may appear to be common sense. Employee appreciation is a potent motivator and reinforcer of positive behaviour,” Nel said.

Nel said: “Recognition reinforces acts and behaviour that improve everyone's working environment. Although recognition is free, it improves employee productivity, engagement, and quality of work.”

The recognition platform has other capabilities that the Division of Organisational Development and Employee Well-being would like to incorporate in the future, and staff can continue to nominate their colleagues for their excellence. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept